"BMS" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonIncredible Lineup of Entertainment — Including Red Panda — Set for Bms Fan Zone During Food City ...
Incredible Lineup of Entertainment — Including Red Panda — Set for Bms Fan Zone During Food City 500 Weekend at Bris Speedway Digest
BMS Band hosts spring concert and awards ceremony - Peak of Ohio
BMS Band hosts spring concert and awards ceremony Peak of Ohio
Evotec earns $10 million milestone as partner advances molecular glue into phase 1 - Drug Discove...
Evotec earns $10 million milestone as partner advances molecular glue into phase 1 Drug Discovery News
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma - Reuters
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma Reuters
BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncolog...
BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncologists Fierce Pharma
Evotec Receives Milestone Payment from BMS for Protein Degradation Collaboration - Contract Pharma
Evotec Receives Milestone Payment from BMS for Protein Degradation Collaboration Contract Pharma
BMS Art on Main Keeps Spotlight on Emotions - Eagle Country 99.3
BMS Art on Main Keeps Spotlight on Emotions Eagle Country 99.3
Physician Views Preview: Can BMS' Sotyktu provide a new oral standard of care for psoriatic arthr...
Physician Views Preview: Can BMS' Sotyktu provide a new oral standard of care for psoriatic arthritis? FirstWord Pharma
Stenhouse optimistic about BMS package - Kingsport Times News
Stenhouse optimistic about BMS package Kingsport Times News
Rotary Hand Seed Slotter BMS – Overseeding Tool For Lawn Patches, 13mm Depth Fine Grass Seed - Ru...
Rotary Hand Seed Slotter BMS – Overseeding Tool For Lawn Patches, 13mm Depth Fine Grass Seed RuhrkanalNEWS
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026 - Business Wire
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026 Business Wire
Braemar (LON:BMS) Shares Pass Above 200-Day Moving Average - Here's What Happened - MarketBeat
Braemar (LON:BMS) Shares Pass Above 200-Day Moving Average - Here's What Happened MarketBeat
Key facts: BMS Q1 Apr 30; BMS‑986506 Phase I Starts, $10M to Evotec - TradingView
Key facts: BMS Q1 Apr 30; BMS‑986506 Phase I Starts, $10M to Evotec TradingView
Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial - Fierce ...
Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial Fierce Biotech
Bristol Myers Squibb Kidney Cancer Trial Tests Valuation And Pipeline Depth - simplywall.st
Bristol Myers Squibb Kidney Cancer Trial Tests Valuation And Pipeline Depth simplywall.st
Battery Management System Market to Reach $55.1 Billion by 2032 — Powering the Electric Revolutio...
Battery Management System Market to Reach $55.1 Billion by 2032 — Powering the Electric Revolution AltEnergyMag
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff - Clinical Trials Arena
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff Clinical Trials Arena
FDA Action Alert: BMS, GSK, Aldeyra and More - BioSpace
Biopharma bites: Layoffs at BMS, Generate's IPO plans, Fortress's voucher sale…and more - FirstWo...
Biopharma bites: Layoffs at BMS, Generate's IPO plans, Fortress's voucher sale…and more FirstWord Pharma
Alex Bowman to miss next three races as he focuses on vertigo recovery - Speedway Digest
Alex Bowman to miss next three races as he focuses on vertigo recovery Speedway Digest
Science Firsthand: Translating the promise of cell therapy - Bristol Myers Squibb
Science Firsthand: Translating the promise of cell therapy Bristol Myers Squibb
Science Firsthand: Making the leap to intentionally designed degraders - Bristol Myers Squibb
Science Firsthand: Making the leap to intentionally designed degraders Bristol Myers Squibb
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments BioSpace
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour - BioSpace
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour BioSpace
Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B - Fierce ...
Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B Fierce Biotech
Champions in Care - Bristol Myers Squibb
Champions in Care Bristol Myers Squibb
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy...
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) Bristol Myers Squibb (BMS)
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for C...
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation Eagle-Tribune
BMS Beats Again Despite Eliquis and Cobenfy Disappointments - BioSpace
BMS Beats Again Despite Eliquis and Cobenfy Disappointments BioSpace
Patient Advocate Foundation Announces $1 Million Donation from Bristol Myers Squibb Foundation - ...
Patient Advocate Foundation Announces $1 Million Donation from Bristol Myers Squibb Foundation Patient Advocate Foundation
Bristol Myers Squibb discloses 247 more layoffs in NJ (updated) - NJBIZ
Bristol Myers Squibb discloses 247 more layoffs in NJ (updated) NJBIZ
Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis - Fie...
Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis Fierce Biotech
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line - BioSpace
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line BioSpace
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immun...
FDA Fast Tracks Anti-MTBR-Tau-Targeting Antibody BMS-986446 for Alzheimer Disease - Neurology Live
FDA Fast Tracks Anti-MTBR-Tau-Targeting Antibody BMS-986446 for Alzheimer Disease Neurology Live
Driving patient-centric care through global patient outreach - Bristol Myers Squibb
Driving patient-centric care through global patient outreach Bristol Myers Squibb
Empowering patients with clarity & confidence through UPL program - Bristol Myers Squibb
Empowering patients with clarity & confidence through UPL program Bristol Myers Squibb
With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm - Fierc...
With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm Fierce Pharma
BMS pens $850M solid tumor pact with T-cell engager biotech Janux - Fierce Biotech
BMS pens $850M solid tumor pact with T-cell engager biotech Janux Fierce Biotech
Science Firsthand: The renaissance of neuroscience R&D - Bristol Myers Squibb
Science Firsthand: The renaissance of neuroscience R&D Bristol Myers Squibb
Building a healthier future together: Strengthening cancer care across Africa through partnership...
Building a healthier future together: Strengthening cancer care across Africa through partnership Bristol Myers Squibb
Chris Shibutani, MD - Bristol Myers Squibb
Chris Shibutani, MD Bristol Myers Squibb
BMS Makes $1.5B Cell Therapy Play With Orbital Takeover - BioSpace
BMS Makes $1.5B Cell Therapy Play With Orbital Takeover BioSpace
Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA - Fierc...
Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA Fierce Biotech
JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority - F...
JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority Fierce Pharma
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical R...
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn European Pharmaceutical Review
Nurse practitioners impact patient care and foster collaboration - Bristol Myers Squibb
Nurse practitioners impact patient care and foster collaboration Bristol Myers Squibb
BMS' Cobenfy TV ad is latest target of FDA untitled letter spree - Fierce Pharma
BMS' Cobenfy TV ad is latest target of FDA untitled letter spree Fierce Pharma
Texas files suit against Sanofi, BMS over 'deceptive' Plavix marketing - Fierce Pharma
Texas files suit against Sanofi, BMS over 'deceptive' Plavix marketing Fierce Pharma
Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market - BioSpace
Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market BioSpace
Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer t...
Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test Fierce Biotech
Protein homeostasis 101: A Q&A with Mark Rolfe - Bristol Myers Squibb
Protein homeostasis 101: A Q&A with Mark Rolfe Bristol Myers Squibb
A global journey through BMS’ R&D hubs - Bristol Myers Squibb
A global journey through BMS’ R&D hubs Bristol Myers Squibb
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities” - Clinical Trials Arena
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities” Clinical Trials Arena
New RayzeBio hub accelerates next-gen cancer therapies - Bristol Myers Squibb
New RayzeBio hub accelerates next-gen cancer therapies Bristol Myers Squibb
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC - BioSpace
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC BioSpace
BMS and Takeda dive into AI data pool, joining peers in collaborative push to unfold the future -...
BMS and Takeda dive into AI data pool, joining peers in collaborative push to unfold the future Fierce Biotech
BMS sells controlling stake in historic US-China pharmaceutical joint venture - Fierce Pharma
BMS sells controlling stake in historic US-China pharmaceutical joint venture Fierce Pharma
Merck & Co., BMS to lay off over 300 staffers in New Jersey - FirstWord Pharma
Merck & Co., BMS to lay off over 300 staffers in New Jersey FirstWord Pharma
Harnessing the Potential of Anti-Cancer Modalities - Bristol Myers Squibb
Harnessing the Potential of Anti-Cancer Modalities Bristol Myers Squibb
With site 'irregularities,' Bristol Myers delays key Cobenfy readout in Alzheimer's psychosis - F...
With site 'irregularities,' Bristol Myers delays key Cobenfy readout in Alzheimer's psychosis Fierce Pharma
BMS plots another DTC platform, this one offering Sotyktu at 86% discount to cash-pay patients - ...
BMS plots another DTC platform, this one offering Sotyktu at 86% discount to cash-pay patients Fierce Pharma
WCLC25: BioNTech, BMS tout second readout for PD-L1/VEGF-A in SCLC - FirstWord Pharma
WCLC25: BioNTech, BMS tout second readout for PD-L1/VEGF-A in SCLC FirstWord Pharma
Dhurandhar 2 Box Office: With 2.4 Million, Ranveer Singh Closes BMS Pre-Sales On Day 0 As The Big...
BMS, Bain Capital team up on autoimmune-focused newco - FirstWord Pharma
BMS, Bain Capital team up on autoimmune-focused newco FirstWord Pharma
BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study - BioSpace
BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study BioSpace
How Bristol Myers Squibb Transformed Working Capital to Fund Its Future - Harvard Business Review
How Bristol Myers Squibb Transformed Working Capital to Fund Its Future Harvard Business Review
Rovi acquires BMS facility in Phoenix and strikes $250M manufacturing deal - Fierce Pharma
Rovi acquires BMS facility in Phoenix and strikes $250M manufacturing deal Fierce Pharma
Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy? - BioSpace
Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy? BioSpace
Bristol Myers Squibb paves way for expansion of Camzyos to adolescent patients - Fierce Pharma
Bristol Myers Squibb paves way for expansion of Camzyos to adolescent patients Fierce Pharma
FDA Action Alert: BMS, GSK, Amgen and More - BioSpace
BMS ups guidance, but its financial prospects fail to capture investor enthusiasm - FirstWord Pharma
BMS ups guidance, but its financial prospects fail to capture investor enthusiasm FirstWord Pharma
BMS snags top neuro researcher from Eisai—Chutes & Ladders - Fierce Biotech
BMS snags top neuro researcher from Eisai—Chutes & Ladders Fierce Biotech
BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates...
BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates BioSpace
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant - BioSpace
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant BioSpace
"Too many patients in rural America face barriers to cardiovascular care — barriers that - Bristo...
"Too many patients in rural America face barriers to cardiovascular care — barriers that Bristol Myers Squibb
BMS boosts cancer trials with Sarah Cannon's clinical research platform - Fierce Biotech
BMS boosts cancer trials with Sarah Cannon's clinical research platform Fierce Biotech
Bristol Myers Squibb Commits to Veeva Vault CRM - Veeva
BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia - Fier...
BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia Fierce Biotech
ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage tr...
ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage trial Fierce Biotech
Rovi’s injectables CDMO rebrands as Rois and acquires BMS facility - European Pharmaceutical Review
Rovi’s injectables CDMO rebrands as Rois and acquires BMS facility European Pharmaceutical Review
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 20...
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 PR Newswire
New BMS Department Head Makes Enthusiastic Return to Purdue to Take on New Leadership Role - Purd...
New BMS Department Head Makes Enthusiastic Return to Purdue to Take on New Leadership Role Purdue University College of Veterinary Medicine
Veterans redefining manufacturing leadership in pharma - Bristol Myers Squibb
Veterans redefining manufacturing leadership in pharma Bristol Myers Squibb
BMS builds a 'world of gratitude' to honor healthcare workers in new PSA - Fierce Pharma
BMS builds a 'world of gratitude' to honor healthcare workers in new PSA Fierce Pharma
BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes - Fierce Biotech
BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes Fierce Biotech
BMS direct platform adds psoriasis drug Sotyktu with deep price cut - FirstWord Pharma
BMS direct platform adds psoriasis drug Sotyktu with deep price cut FirstWord Pharma
Bristol Myers Squibb Announces Dividend - Business Wire
Bristol Myers Squibb Announces Dividend Business Wire
C2C4C marks 12 inspiring years advancing cancer research - Bristol Myers Squibb
C2C4C marks 12 inspiring years advancing cancer research Bristol Myers Squibb
Dhurandhar 2 Box Office Day 2 Morning Trends: Hits Half Million Sold Tickets, Already Earns More ...
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy - BioSpace
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy BioSpace
JP Morgan 2026 Preview: Bristol Myers Squibb’s Continued Growth - Pharmaceutical Executive
JP Morgan 2026 Preview: Bristol Myers Squibb’s Continued Growth Pharmaceutical Executive
Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma - Fierce Biotech
Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma Fierce Biotech
BMS scores 5th indication for Breyanzi with FDA marginal zone lymphoma nod - Fierce Pharma
BMS scores 5th indication for Breyanzi with FDA marginal zone lymphoma nod Fierce Pharma
BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence - Fierce Biotech
BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence Fierce Biotech
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital - Pharma...
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital Pharmaceutical Executive
BMS, Pfizer launch direct-to-consumer push for Eliquis in the US - FirstWord Pharma
BMS, Pfizer launch direct-to-consumer push for Eliquis in the US FirstWord Pharma
Bristol Myers Squibb to buy RNA start-up for $1.5 billion - Chemical & Engineering News
Bristol Myers Squibb to buy RNA start-up for $1.5 billion Chemical & Engineering News
Novo, BMS Layoffs Hit New Jersey Hard With More Than 500 Left Jobless - BioSpace
Novo, BMS Layoffs Hit New Jersey Hard With More Than 500 Left Jobless BioSpace
BMS shuffles R&D leadership, bringing in AstraZeneca exec as new CMO - FirstWord Pharma
BMS shuffles R&D leadership, bringing in AstraZeneca exec as new CMO FirstWord Pharma